Activité à long terme de l'acétate de glatiramère dans le traitement de la sclérose en plaques : état des connaissances

The information collected from prospective long-term follow-up of patients treated with glatiramer acetate extending out to 10 years provide clear evidence for the long-term efficacy and adequate safety of this immunomodulatory treatment in the treatment of relapsing-remitting multiple sclerosis over a period of at least 10 years.